Janus Living enters mid-June with a striking divergence at its core: short sellers have nearly tripled their position over the past month while every analyst covering the stock has been raising targets.
The short-side buildup is the most arresting feature of the current setup. Estimated short shares have risen 148% over the past 30 days, reaching roughly 4.2 million shares as of June 9 — up 61% on the week alone. That is a rapid accumulation by any measure. The ORTEX short score has climbed from 35 in late May to 48, the highest reading in the recent history available, reflecting the acceleration. What makes the move unusual is its context: borrow remains cheap and easy. Cost to borrow is running near 2.1%, elevated from the sub-1% levels of late May but still modest. Availability is extraordinarily loose — 50 million shares remain available to lend, putting availability at over 1,000% of current short interest. Short sellers are building positions with minimal friction, which means there is no mechanical squeeze pressure from the lending market at this stage. The float-percent figure is unavailable in the data, but the raw share count and trajectory are hard to ignore.
The analyst community is reading this stock very differently from the shorts. Every recent rating action has been a target raise, with no downgrades. Wells Fargo lifted its target from $27 to $31, Barclays moved from $26 to $30, RBC Capital from $27 to $30, and Scotiabank from $28 to $30. This week, Keybanc raised its target to $29 from $28 while maintaining Overweight. Goldman Sachs initiated in April at Neutral with a $27 target — the lone cautious voice in an otherwise bullish chorus. The mean price target now sits at $29.50, implying roughly 16% upside from the June 9 close of $25.42. Bulls point to strong organic growth potential in the senior housing REIT space, a RIDEA-structured portfolio, and a solid balance sheet. The bear case centres on competition for deals, reliance on cash deployment, and a life plan community asset class that still carries a learning curve for investors.
The stock is down about 9% over the past month, which appears to be the catalyst pulling short interest higher even as analysts chase the name up. The recent earnings record offers mild reassurance: the May 6 print produced a 4.5% one-day gain and held into the following week. The next scheduled earnings event is not yet confirmed. Valuation sits at roughly 75x trailing earnings — elevated for a REIT — and EV/EBITDA near 16.7x, which has compressed about 1.2 turns over 30 days as the stock has pulled back. Price-to-book is 2.6x.
One further data point worth watching: Healthpeak Properties holds 74% of shares outstanding, a parent-level stake that concentrates the float considerably. All other holders, including MFS, PGIM, Long Pond Capital, and BlackRock, hold small single-digit slices of a relatively thin tradeable float. That concentration means the short-interest buildup involves a narrow pool of freely circulating shares, even if raw lending availability looks abundant.
The setup heading into the coming weeks is therefore a tug-of-war between an accelerating short position and a sell-side that keeps marking targets higher — with the stock sitting 16% below consensus and borrow conditions that currently offer no catalyst to force either side's hand.
See the live data behind this article on ORTEX.
Open JAN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
